Table 1.
Main characteristics at inclusion
| Main demographic characteristics at inclusion | |
|---|---|
| Age, mean ± SD (years) | 49.2 ± 19.4 |
| No. of female/No. of male | 45/53 |
| Body mass index, mean ± SD (kg/m2) | 25.5 ± 4.4 |
| Diabetes mellitus, n (%) | 18 (18.4%) |
| Serum creatinine at inclusion, median (IQR)(µmol/L) | 127.5 (80.5–224.3) |
| eGFR according to MDRD, median (IQR)(mL/min/1.73 m2) | 47.7 (23.8–87.5) |
| Patients with renal failure, n (%) | 61 (62.2%) |
| Patients with nephrotic syndrome, n (%) | 44 (44.9%) |
| Previous immunosuppressive agent, n (%) | 71 (72.4%) |
| Steroids, n (%) | 69 (70.4%) |
| CYC, n (%) | 36 (36.7%) |
| Total dose CYC, mean ± SD (g) | 7 ± 4.05 |
| Interval since CYC/RTX, median (IQR) (months) | 9.4 (1.6–43.3) |
| MMF, n (%) | 32 (32.6%) |
| Interval since MMF/RTX, median (IQR) (months) | 0.0 (0.0–12.4) |
| Calcineurine inhibitor, n (%) | 16 (16.3%) |
| Interval since CNI/RTX, median (IQR) (months) | 2.8 (0.0–8.4) |
| Azathioprine, n (%) | 8 (8.1%) |
| Interval since AZA/RTX, median (IQR) (months) | 15.1 (0.2–18.8) |
| Rituximab protocol administration | |
| 375 mg/m2/week ×4 infusions, n (%) | 58 (59.1%) |
| 1 g/2 weeks ×2 infusions, n (%) | 19 (19.4%) |
| Other regimen, n (%) | 21 (21.4%) |
| Reinjection after initial protocol, n (%) | 37 (37.7%) |
| Cumulate dose, median (IQR) (mg) | 2800 (2000–3562) |
| Immunosuppressive therapy prescribed within the 12 months following RTXs, n (%) | 75 (76.5%) |
| Steroids, n (%) | 68 (69.4%) |
| Plasmapheresis, n (%) | 19 (19.4%) |
| Patients with other immunosuppressive therapy, n (%), including | 41 (41.8%) |
| MMF, n (%) | 26 (26.5%) |
| CNI, n (%) | 12 (12.4%) |
| AZA, n (%) | 6 (6.1%) |
| CYC, n (%) | 5 (5.1%) |
| Chloraminophen, n (%) | 2 (2%) |
| Lenalidomide, n (%) | 1 (1%) |